Moleculin Biotech, Inc.
$2.56
▲
4.04%
2026-04-21 08:04:00
moleculin.com
NCM: MBRX
Explore Moleculin Biotech, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.66 M
Current Price
$2.56
52W High / Low
$28.61 / $1.79
Stock P/E
—
Book Value
$4.69
Dividend Yield
—
ROCE
-164.37%
ROE
-2.56%
Face Value
—
EPS
$-28.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
1.67
Debt / Equity
2.39
Current Ratio
1.41
Quick Ratio
1.41
Forward P/E
-0.02
Price / Sales
—
Enterprise Value
$5.46 M
EV / EBITDA
-0.22
EV / Revenue
—
Rating
None
Target Price
$21
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioCardia, Inc. | $1.25 | — | $12.91 M | — | -843.83% | -9.5% | $3.2 / $1 | $0.08 |
| 2. | Aclaris Therapeutics, Inc. | $4.25 | — | $512.53 M | — | -53.3% | -50.2% | $4.89 / $1.08 | $0.85 |
| 3. | Equillium, Inc. | $2.01 | — | $127.09 M | — | -81.63% | -94% | $2.7 / $0.27 | $0.47 |
| 4. | Cognition Therapeutics, Inc. | $1.12 | — | $106.33 M | — | -70.77% | -88.59% | $3.83 / $0.22 | $0.39 |
| 5. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 6. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 7. | Neumora Therapeutics, Inc. | $2.19 | — | $391.39 M | — | -152.06% | -1.21% | $3.65 / $0.61 | $0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -7.53 M | -5.91 M | -5.72 M | -5.94 M | -6.64 M | — |
| Net Profit | 15.55 M | -25.4 M | -7.64 M | -6.44 M | -1.88 M | — |
| EPS in Rs | 2.91 | -4.76 | -1.43 | -1.21 | -0.35 | -47.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -25.1 M | -26.64 M | -29.63 M | -30.64 M |
| Net Profit | -33.56 M | -26.05 M | -29.77 M | -29.02 M |
| EPS in Rs | -6.29 | -4.88 | -5.58 | -5.44 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 22.13 M | 16.93 M | 38.22 M | 57.42 M |
| Total Liabilities | 7.12 M | 5.72 M | 12.14 M | 5.23 M |
| Equity | 15.01 M | 11.21 M | 26.07 M | 52.19 M |
| Current Assets | 9.69 M | 5.19 M | 26.27 M | 45.6 M |
| Current Liabilities | 6.85 M | 5.36 M | 6.82 M | 4.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.73 M | -23.86 M | -23.59 M | -27.64 M |
| Investing CF | 0 M | -0.01 M | -0.12 M | -0.07 M |
| Financing CF | 27.28 M | 4.63 M | 4.14 M | -0.02 M |
| Free CF | -22.73 M | -23.88 M | -23.71 M | -27.71 M |
| Capex | — | -0.01 M | -0.12 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 12.5% | -2.56% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-01 | 1:0.04 |
| 2024-03-22 | 1:0.0666667 |